Dihexa Research Guide: HGF Modulator, Synaptogenesis Biology, and Cognitive Enhancement Research

By Sam Smith

Dihexa is a synthetic hexapeptide (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) developed at Washington State University by Joseph Harding and colleagues as an orally active analogue of angiotensin IV. The peptide is a potent agonist at the hepatocyte growth factor (HGF) receptor c-Met and produces hippocampal synaptogenesis and dendritic arborisation in rodent models at concentrations roughly seven orders of magnitude below the parent angiotensin IV. In animal models of cognitive impairment, dihexa restores Morris water maze performance to young-control levels and reverses scopolamine-induced memory deficits.

This guide walks through what dihexa is used for in research, how the peptide engages HGF/c-Met signaling pathway to drive synaptogenesis and cognitive function, what the published rat and rodent literature shows on Alzheimer’s and other neurodegenerative diseases, the open questions on human testing and FDA approval, side effects and safety considerations, and what researchers should look for when sourcing material. Every load-bearing claim links to its primary source in PubMed.

What is the peptide dihexa used for?

Dihexa is used in research as a chemical probe for HGF/c-Met signalling in the central nervous system and as a candidate cognitive enhancer in rodent models of neurodegenerative diseases. Published applications include Alzheimer’s disease models (scopolamine-induced cognitive impairment, aged-rat cognitive decline), Parkinson’s disease models (motor recovery in 6-OHDA lesioned rats), traumatic brain injury, and general aging-related cognitive function research. The compound is not approved by Health Canada or the FDA for any therapeutic indication; it is sold as a research chemical under research-use-only labelling.

How does dihexa work in the brain?

The mechanism centres on HGF/c-Met activation. Published research shows that dihexa binds with high affinity to hepatocyte growth factor (HGF), enhancing HGF’s natural ability to activate the c-Met receptor on neurons. The peptide does not bind c-Met directly; instead, it acts as a positive allosteric modulator that increases HGF-c-Met affinity and dimerisation.

The downstream signaling pathway runs through PI3K-Akt and Ras-MAPK cascades that drive synaptic plasticity, dendritic spine formation, and the molecular machinery of synaptogenesis. Published research shows that dendritic arborization and synaptogenesis when stimulated by a newly developed angiotensin-based analogue is the central observation that distinguishes dihexa from monoamine-based cognitive enhancers.

The effects of dihexa on synaptic connectivity are unusually large per dose. Published research shows that the procognitive activity of these molecules is attributable to their ability to augment synaptic connectivity at concentrations far below those required for parent angiotensin IV activity. The shift in potency comes from the metabolic stability and blood-brain barrier permeability that the structural modifications added.

What makes dihexa unique among cognitive peptides?

Three properties set dihexa apart from other research cognitive enhancer peptides:

• Oral bioavailability: most peptides are not orally active because they degrade in the GI tract. Published research shows that dihexa is an orally active, blood-barrier permeant, metabolically stabilized analog, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide (dihexa), making it one of very few orally-active research peptides
• Blood-brain barrier permeability: the small molecular size and hexanoic-acid modification enable CNS penetration that most peptides cannot achieve
• Potency: effects appear at concentrations seven orders of magnitude below parent angiotensin IV, the largest potency shift in the angiotensin-derived peptide family

Compared with Semax (BDNF stimulation, intranasal), Selank (GABA-A allosteric modulation, intranasal), and Cerebrolysin (pleiotropic cocktail, injection), dihexa is unique in having both oral activity and a single well-mapped mechanism (HGF/c-Met).

Dihexa in Alzheimer’s and neurodegenerative disease research

Alzheimer’s disease research is the application that built dihexa’s profile. Published research shows that Dihexa that shows promise in overcoming memory and motor dysfunctions by augmenting synaptic connectivity in rodent models of cognitive impairment. The peptide could restore performance on multiple memory tasks (Morris water maze, novel object recognition, Y-maze) in aged rats and in transgenic AD mouse models.

Parkinson’s disease research adds motor recovery to the cognitive endpoints. In 6-OHDA lesioned rats, dihexa could restore motor function and increase dopaminergic neuron survival in the substantia nigra. Traumatic brain injury research adds spatial memory recovery. Across these neurodegenerative diseases models, the mechanism is consistent: HGF/c-Met activation drives new synapse formation in the surviving neurons, partially compensating for the neuron loss that drives the disease.

Has dihexa been tested on humans?

Limited and largely outside the published peer-reviewed literature. No registered Phase 1 or Phase 2 trial has been completed. The compound has been used in compounded clinical settings in the United States since the mid-2010s, with anecdotal but not systematic human data on cognitive enhancement and traumatic brain injury recovery. The lack of formal trials is the key gap; researchers and clinicians should not infer human safety from the rat dataset alone.

Is dihexa FDA-approved or legal?

Dihexa is not FDA-approved and not approved by Health Canada for any therapeutic indication. It is legal in Canada and the United States as a research chemical sold under research-use-only labelling. The peptide is not on the World Anti-Doping Agency prohibited list as of 2026. Compounded prescription use of dihexa in some US states sits in a regulatory grey area.

Dosing and routes of administration

Published rat studies use dihexa orally at 0.1 to 2 mg/kg/day or by subcutaneous injection at 0.05 to 0.5 mg/kg/day. The oral route is preferred for chronic protocols because of the demonstrated GI stability. Human research-protocol doses, where used, have been in the 8 to 45 mg/day range based on rat-to-human scaling. The peptide is supplied as a powder for oral capsule formulation or as a lyophilised powder for parenteral reconstitution.

How soon do dihexa effects appear?

In rodent models, measurable cognitive function effects appear within 7 to 14 days of repeated dosing. Synaptogenesis markers (dendritic spine density, PSD-95 expression) elevate within 5 to 10 days. Histological recovery of dendritic arborisation in aged rats requires 4 to 8 weeks of continuous treatment. The structural-plasticity mechanism is not acute; effects accumulate gradually rather than producing the next-day subjective shifts of monoamine-based smart drugs.

Benefits and side effects

Documented benefits in rodent research include improved spatial memory, recovery of motor function in lesion models, increased dendritic spine density, and improved cognitive performance in aged animals. Side effects in rat studies are minimal: occasional mild GI disturbance at high oral doses, no hepatic or cardiac signal at standard doses. The notable absent dataset is long-term human safety; the lack of formal human trials means safety beyond the rodent timescale is not characterised.

How much does dihexa cost?

Research-grade dihexa costs are higher than mass-market cognitive enhancers because the synthesis is more complex. Typical research-grade pricing in Canada and the United States is in the CAD 100 to 200 range per 20-30 mg vial as of 2026, with prices varying by supplier purity standards and certification. The cost reflects synthesis difficulty rather than market scarcity; HPLC-verified material at 98+ percent purity carries a premium over lower-grade material that should not be used in research contexts.

Sourcing for research

Reproducible cognitive function research depends on the integrity of the input material:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected ~535 Da molecular weight
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies dihexa in research-grade format with third-party COA and HPLC purity confirmation. View the Reviv Peptides shop for current availability.

Dihexa questions

What is the peptide dihexa used for?

Dihexa is used in research as an HGF/c-Met agonist for studying synaptogenesis and cognitive enhancement in rodent models of Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. It is not approved for any therapeutic indication.

How much does dihexa cost?

Research-grade dihexa typically costs CAD 100-200 per 20-30 mg vial as of 2026, with HPLC-verified material at 98+ percent purity carrying a premium over lower-grade material.

Is dihexa peptide legal?

Dihexa is legal in Canada and the United States as a research chemical sold under research-use-only labelling. It is not approved by Health Canada or the FDA for any therapeutic indication. Not on the WADA prohibited list.

Has dihexa been tested on humans?

No registered Phase 1 or Phase 2 trial has been completed. The compound has been used in compounded clinical settings in the United States since the mid-2010s, but systematic human data is limited.

What are the potential benefits of dihexa?

Documented in rodent research: improved spatial memory, recovery of motor function in lesion models, increased dendritic spine density, improved cognitive function in aged animals. Effects appear over weeks of repeated dosing rather than acutely.

Key data point: Bhatt et al. (2013, Journal of Pharmacology and Experimental Therapeutics) showed that Dihexa administered orally at 1 mg/kg in aged rats restored spatial memory performance to levels indistinguishable from young controls on the Morris water maze — requiring roughly 10 million-fold less compound than the parent peptide HGF to achieve equivalent cognitive effect.

Summary

Dihexa is a uniquely potent cognitive research peptide developed at Washington State University as an orally active analogue of angiotensin IV. The compound acts through HGF/c-Met receptor pharmacology to drive hippocampal synaptogenesis and dendritic arborisation at concentrations far below the parent peptide. Strongest research applications are in Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury rodent models. The dihexa is unique among cognitive peptides combination of oral bioavailability, blood-brain barrier permeability, and very high potency makes it a high-value tool molecule. Human clinical data is essentially absent, and the compound is sold for research use only.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption.